Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study.

Publication date: Jul 17, 2023

COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction. Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses. 26 patients (out of 37) with complete outcome data were included in the analysis (age ~59. 0 years; BMI ~ 30. 4, 35% women). Patients were hypermetabolic at T0 (30. 3 +/- 4. 0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): -5. 4 (-6. 8, -4. 1) kcal/kg FFM/day, p 

Concepts Keywords
Corticosteroids Beta
Diabetes Caused
Insulinogenic Covid
New Day


Type Source Name
disease MESH COVID-19
disease MESH hyperglycemia
disease IDO cell
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease IDO history
disease IDO disposition
drug DRUGBANK Nitrogen

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *